# Do GLP-1 Drugs Help IBS? Coded Symptoms Fell by Two to Four Points | This GLP Do GLP-1 drugs help IBS? A matched analysis of 6,665 per arm found lower coded rates of diarrhea, constipation, pain and bloating | and why coding may explain all of it. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/do-glp1-drugs-help-ibs Updated: 2026-09-17 Published: 2026-09-17 [← Research](https://thisglp.com/research) Evidence # Do GLP-1 Drugs Help IBS? Coded Symptoms Fell by Two to Four Points Diarrhea, constipation, pain and bloating were all coded less often in treated IBS patients. Coded is doing a lot of work in that sentence. [This GLP Editorial Team](https://thisglp.com/about)September 20268 min read Coded in 90 days — on a GLP-1 vs not · on one · not on one · abdominal pain · 31.6 · 35.8 · constipation · 19.8 · 22 · diarrhea · 8.9 · 10.6 · bloating · 8.3 · 10.9 · Gaps of 2 to 4 points, in about 6,665 people per arm. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). Coded symptoms fell, which is not the same thing as bowels settling. In a matched analysis of 6,665 people per arm who already had irritable bowel syndrome, abdominal pain was coded in 31.6% against 35.8%, constipation in 19.8% against 22.0% and bloating in 8.3% against 10.9% [\[1\]](https://thisglp.com/research/do-glp1-drugs-help-ibs#ref-1). Every one of those outcomes is a billing code entered at a visit, chronic diarrhea included at 8.9% against 10.6%, and the gaps run two to four percentage points. Nothing here was a symptom diary, and no randomized trial has tested a GLP-1 in irritable bowel syndrome. ## Key takeaways - A matched analysis compared people with irritable bowel syndrome who started a GLP-1 drug against those who did not, with 6,665 per arm in the 90-day cohort. - Coded rates were lower on treatment for chronic diarrhea (8.9% vs 10.6%), constipation (19.8% vs 22.0%), abdominal pain (31.6% vs 35.8%) and bloating (8.3% vs 10.9%). - These are the same symptoms the drugs are best known for causing. - Every outcome is a diagnostic code, and differences in symptom recurrence were smaller than differences in first occurrence. Nausea, diarrhea, [constipation](https://thisglp.com/research/does-ozempic-cause-constipation) and bloating are the defining side effects of this drug class, described from the mechanism side in [nausea and appetite on one circuit](https://thisglp.com/research/why-do-glp1-drugs-cause-nausea). So a study finding fewer of those symptoms recorded in people who already have irritable bowel syndrome is worth reading carefully [\[1\]](https://thisglp.com/research/do-glp1-drugs-help-ibs#ref-1). The direction is consistent across every outcome measured. In the 90-day cohort, chronic diarrhea was coded in 8.9% of the treated group against 10.6% of controls, constipation in 19.8% against 22.0%, abdominal pain in 31.6% against 35.8%, and bloating in 8.3% against 10.9%. Similar patterns appeared in the diarrhea-predominant and constipation-predominant subtypes. A code is not a symptom Every outcome here is a diagnostic code entered at a visit. Irritable bowel syndrome is defined by fluctuating gut symptoms, so what gets coded depends heavily on what a patient raises and a clinician records on a given day. Someone who develops new gut symptoms shortly after starting a weight drug may reasonably describe them as a drug side effect rather than as their IBS — and the coded IBS symptom then does not appear. That mechanism would produce exactly this result without anyone's gut improving. The authors provide a clue that points the same way. They note that differences in outcome recurrence — how many separate episodes people had — were smaller than differences in incidence. If the drug were genuinely settling irritable bowels, you would expect ongoing symptom burden to fall at least as much as first occurrences. A gap concentrated in first coding is more consistent with a change in how symptoms are attributed than in how often they happen. ## Two other guts, measured the same year The same slowing mechanism has been read in two other settings and it lands differently in each. At the severe end, a systematic review searching four databases to October 2025 found twelve case reports covering thirteen patients with drug-associated gastroparesis worldwide [\[2\]](https://thisglp.com/research/do-glp1-drugs-help-ibs#ref-2). At the other end, a chart review of 117 patients having elective posterior lumbar fusion found bowel function returning sooner in GLP-1 users, at 1.35 days against 1.90 (P = 0.013) [\[3\]](https://thisglp.com/research/do-glp1-drugs-help-ibs#ref-3). A drug that slows gut transit producing an earlier return of bowel function is the opposite of the expected direction, and the reading of it is in [the post-surgical cohort](https://thisglp.com/research/the-bowels-woke-up-sooner). None of the three findings contradicts the others; they describe one mechanism meeting three different guts. The absolute differences are also modest: two to four percentage points across the outcomes. With roughly 6,665 people in each arm, small differences reach significance easily, and the P values say nothing about whether a patient would notice — the distinction drawn in [the FLOW numbers needed to treat](https://thisglp.com/research/twenty-two-thirteen-seventeen) applies here too. A real effect is nonetheless plausible. Slower gastric emptying could genuinely help diarrhea-predominant IBS, and weight loss reduces the systemic inflammation that some IBS phenotypes involve. What this design cannot do is separate that from a coding artifact, and a prospective study with symptom diaries rather than billing codes would settle it — the same gap running through [the Crohn's disease cohort](https://thisglp.com/research/do-glp1-drugs-help-crohns-disease) and [the gastroparesis evidence](https://thisglp.com/research/do-glp1-drugs-cause-gastroparesis). ## Frequently asked Do GLP-1 drugs help IBS? Coded symptom rates were lower in a matched analysis of people who already had IBS — abdominal pain 31.6% against 35.8%, bloating 8.3% against 10.9%. No randomized trial has tested one in IBS, and every outcome here is a billing code. Do these drugs improve irritable bowel syndrome? Coded rates of IBS symptoms were lower among treated patients, but every outcome is a billing code rather than a measured symptom, and the pattern is also consistent with symptoms being attributed to the drug instead of the IBS. How large were the differences? Two to four percentage points across outcomes — for example abdominal pain in 31.6% against 35.8%. With about 6,665 people per arm, small gaps reach statistical significance readily. Is there a plausible mechanism? Yes. Slowed gastric emptying could help diarrhea-predominant IBS, and weight loss reduces inflammation relevant to some phenotypes. This study design cannot distinguish that from a coding effect. ## Sources 1. \[1\] Khan SA, Marasini A, Shrestha A, Bharadwaj HR, et al. (2026). Impact of GLP-1 Analogue Therapy on Gastrointestinal Outcomes in Patients with Irritable Bowel Syndrome: A Real-World TriNetX Analysis Digestive Diseases and Sciences. [PMID 42570075](https://pubmed.ncbi.nlm.nih.gov/42570075/) 2. \[2\] Olubodun T, et al. (2026). Gastroparesis induced by glucagon-like peptide-1 receptor agonists: A systematic review of clinical features, diagnosis, management, and outcomes PLOS ONE. [PMID 42594084](https://pubmed.ncbi.nlm.nih.gov/42594084/) 3. \[3\] Fano A, Oris RJ, Dalton J, Baidya J, Ng M, Baek G, Tarawneh O (2025). GLP-1 Agonist Use Leads to Earlier Return of Bowel Function Following Lumbar Fusion Spine. [PMID 41400023](https://pubmed.ncbi.nlm.nih.gov/41400023/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes)